Clinical trials in ALS: What did we learn from recent trials in humans?

Neurodegenerative Diseases

Volumn 2, Issue 3-4, 2006, Pages 208-214

  Meininger, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Clinical trials in ALS; Prognostic factors in ALS; Survival

Indexed keywords

ALPHA TOCOPHEROL; CREATINE; CREATININE; GABAPENTIN; PENTOXIFYLLINE; RILUZOLE; TOPIRAMATE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; COMPREHENSION; COUGHING; CREATININE BLOOD LEVEL; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG EFFECT; DRUG SAFETY; DRUG TARGETING; FASCICULATION; FRANCE; FUNCTIONAL ASSESSMENT; GENDER; GENETIC HETEROGENEITY; HUMAN; LEARNING; MEDICAL LITERATURE; MUSCLE WEAKNESS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; POINT OF CARE TESTING; POPULATION SIZE; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; REVIEW; SCORING SYSTEM; SPASTICITY; STANDARD; SURVIVAL RATE; SURVIVAL TIME; SWALLOWING; VITAL CAPACITY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CLINICAL TRIALS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; PROGNOSIS; RILUZOLE;

EID: 33744809339     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000089627     Document Type: Review

References (41)

1. Guiloff RJ, Goonetilleke A: Natural history of amyotrophic lateral sclerosis. Observations with the Charing Cross Amyotrophic Lateral Sclerosis Rating Scales. Adv Neurol 1995;68:185-198.
2. Jablecki CK, Berry C, Leach J: Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 1989;12:833-841.
3. Christensen PB, Hojer-Pederson E, Jensen NB: Survival of patients with amyotrophic lateral sclerosis in two Danish counties. Neurology 1990;40:600-604.
4. Eisen A, Schulzer M, Macneil M, Pant B: Duration of amyotrophic lateral sclerosis in age dependent. Muscle Nerve 1993;16:27-32.
5. Haverkamp LJ, Appel V, Appel SH: Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995;118:707-719.
6. Lee JRJ, Annegers JF, Appel SH: Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207-215.
7. Preux PM, Couratier P, Boutros-Toni F, et al: Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors. Neuroepidemiology 1996;16:153-160.
8. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V: Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
9. Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ: Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci 1997;152(suppl 1): S10-S17
10. Stambler N, Charatan M, Cedarbaum JM, et al: Prognostic indicators of survival in ALS. Neurology 1998;50:66-72.
11. Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P: Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999;53:1059-1063.
12. Thijs V, Peeters E, Theys P, Matthijs G, Robberecht W: Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population. Acta Neurol Belg 2000;100:84-90.
13. Armon C, Graves MC, Moses D, Forte DK, Sepulveda L, Darby SM, et al: Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve 2000;23:874-882.
14. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A: Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3:15-21.
15. Del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G: Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60:813-819.
16. Kaufmann P, Levy G, Thompson JLP, Del-Bene ML, Battista V, Gordon PH, Rowland LP, Levin B, Mitsumoto H: The ALSFRSr predicts survival time in an ALS clinic population. Neurology 2005;64:38-43.
17. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia Acosta S, Meininger V: Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:37-44.
18. Brooks B: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial 'Clinical limits of amyotrophic lateral sclerosis'. J Neurol Sci 1994;124(suppl):96-107.
19. Paulhan J, Nuissier J, Quintard B, Cousson F, Bourgeois M: La mesure de coping. Traduction et validation françaises de l'échelle de Vitaliano. Ann Méd Psychol 1994;152:292-299.
20. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
21. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al: The Mini-International Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33.
22. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED: Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familiar amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
23. Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, Hager C, Ludolph AC, on behalf of the German Vitamin E/ALS Study Group: High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 2005;112:649-660.
24. Desnuelle C, Dib M, Garrel C, Favier A: A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole-Tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:9-18.
25. Miller RG, Moore DH 2nd, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, Bryan W, Ravits J, Yuen E, Neville H, Ringel S, Bromberg M, Petajan J, Amato AA, Jackson C, Johnson W, Mandler R, Bosch P, Smith B, Graves M, Ross M, Sorenson EJ, Kelkar P, Parry G, Olney R, Western ALS Study Group: Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-848.
26. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF: Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999:3:347-350.
27. Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF: Additive neuroprotective effects of creatine and cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004:3:576-582.
28. Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, Wokke JH, Franssen H, van den Berg LH: A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437-445.
29. Skradski S, White H: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 2000;41(suppl 1):S45-S47.
30. Maragakis N, Jackson M, Ganel R, Rothstein J: Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. Neurosci Lett 2003;338:107-110.
31. Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, Jacobs M, Rothstein JD, Appel SH, Pascuzzi RM, Heiman-Patterson TD, Donofrio PD, David WS, Russell JA, Tandan R, Pioro EP, Felice KJ, Rosenfeld J, Mandler RN, Sachs GM, Bradley WG, Raynor EM, Baquis GD, Belsh JM, Novella S, Goldstein J, Hulihan J, Northeast ALS Consortium: A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-464.
32. Kiaei PS, Kaipiani K, Hensley K, Stewart C, Chen J, Calingasan NY, Beal MF: Pentoxifylline and revlimide block the TNF-α-mediated motor neuron death in transgenic mouse model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(suppl 2):14-15.
33. Schweighoffer F, Ait-Ikhlef A, Resink AL, Brinkman B, Melle-Milovanovic D, Laurent-Puig P, Kearsey J, Bracco L: Qualitative gene profiling: a novel tool in genomics and in pharmacogenomics that deciphers messenger RNA isoforms diversity. Pharmacogenomics 2000;1:187-197.
34. Heemskerk J, Tobin AJ, Ravina B: From chemical to drug: neurodegeration drug screening and the ethics of clinical trials. Nat Neurosci 2002;5:1027-1029.
35. Kaufmann P, Levy G, Thompson JLP, Del-Bene ML, Battista V, Gordon PH, Rowland LP, Levin B, Mitsumoto H: The ALSFRSr predicts survival time in an ALS clinic population. Neurology 2005;64:38-43.
36. Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME, on behalf of the NEALS Consortium: Functional outcome measures as clinical trial endpoints in ALS. Neurology 2004;63:1933-1935.
37. Criggs RC: Finding a treatment for ALS: a practical, meaningful clinical endpoint. Neurology 2004;63:1765.
38. Brooks B, Sanjak M, Belden D, Juhasz-Poscine K, Waclawik A, DePaul R, Dogan S, Maser A, Roelke K, Laird M, Malinowski L, Shannon J, Roelke C: Natural history of amyotrophic lateral sclerosis - impairment, disability, handicap; in Brown R Jr, Meininger V, Swash M (eds): Amyotrophic Lateral Sclerosis. London, Dunitz, 2000, pp 31-58.
39. Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC: Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol 2003;251:1080-1084.
40. Meininger V, Bensimon G, Bradley WG, Brooks B, Douillet P, Eisen A, Lacomblez L, Leigh PN, Robberecht W: Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:1-11.
41. Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, Hoagland RJ, Parry GJ, Ross MA, Stromatt SC: A placebo-controlled trial of recombinant human ciliary neurotrophic factor in amyotrophic lateral sclerosis. Ann Neurol 1996;39:256-260.